Developing a Novel, Oral ChemR23 Agonist
for Treating Chronic Immune Disorders and Cancer
Thetis is a clinical stage biopharmaceutical company developing a first-in-class, oral Resolvin E1 drug (TP-317) for treating mild-to-moderate inflammatory bowel disease (IBD) and solid tumor cancers.
Unique features of TP-317 *
Novel Mechanism
Resolvin E1 (RvE1) is an agonist of ChemR23, a GPCR expressed on myeloid cells and lymphocytes. Activation of ChemR23 by RvE1 promotes innate and adaptive immunity to restore immune homeostasis.
Safety Premium
Based on nonclinical and clinical safety data with oral RvE1, TP-317 is anticipated to be safe and well tolerated when given as monotherapy or as adjunct to other therapies.
Clinical Stage
A Phase 1 study in healthy volunteers with TP-317 is currently underway in Australia. Toxicology and manufacturing activities have been completed or are underway to support rapid initiation of patient trials.
Key Advantages
Adjunctive use of TP-317 has prospects to raise the efficacy ceiling encountered by existing therapeutic approaches, with no additional safety burden.
Strong preclinical data of single-agent efficacy suggest that TP-317 has prospects to be used as chronic therapy for maintenance of remission.
For certain therapeutic targets, TP-317 could be formulated for parenteral, inhalable, sublingual or topical administration.
TP-317 offers expansion opportunities in multiple immune disorders and solid tumor cancers across stages of disease.
* TP-317 is an investigational drug product that has not been approved by the U.S. Food and Drug Administration.